Bellicum Pharmaceuticals Inc (BLCM) : Simplex Trading scooped up 14,336 additional shares in Bellicum Pharmaceuticals Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 7, 2016. The investment management firm now holds a total of 17,210 shares of Bellicum Pharmaceuticals Inc which is valued at $336,456.Bellicum Pharmaceuticals Inc makes up approximately 0.04% of Simplex Trading’s portfolio.
Other Hedge Funds, Including , Bnp Paribas Arbitrage Sa boosted its stake in BLCM in the latest quarter, The investment management firm added 606 additional shares and now holds a total of 1,454 shares of Bellicum Pharmaceuticals Inc which is valued at $30,141.
Bellicum Pharmaceuticals Inc closed down -0.74 points or -3.65% at $19.55 with 2,04,035 shares getting traded on Friday. Post opening the session at $20.3, the shares hit an intraday low of $19.37 and an intraday high of $20.4 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, Bellicum Pharmaceuticals Inc reported $-0.61 EPS for the quarter, missing the analyst consensus estimate by $ -0.03 based on the information available during the earnings call on Aug 8, 2016. Analyst had a consensus of $-0.58.Analysts expectations of $ .06.During the same quarter in the previous year, the company posted $-0.40 EPS.
Many Wall Street Analysts have commented on Bellicum Pharmaceuticals Inc. Bellicum Pharmaceuticals Inc was Upgraded by Citigroup to ” Buy” on Aug 9, 2016.
Bellicum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer including hematological cancers and solid tumors as well as orphan inherited blood disorders. The Company is using its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system in real time. The Company is developing next-generation product candidates in the areas of cellular immunotherapy including hematopoietic stem cell transplantation (HSCT) chimeric antigen receptors (CAR) T cells therapy and dendritic cell vaccines. The Company’s product candidates include BPX-501 BPX-201 BPX-401 BPX-601 and BPX-701. It is also engaged in other development programs such as CIDeCAR for the treatment of solid tumors and CaspaCIDe TCR for the treatment of hematological cancers.